Immunocore Holdings plc (NASDAQ:IMCR) is one of the 12 Best UK Stocks to Buy According to Hedge Funds.

On March 16, 2026, Jefferies downgraded Immunocore Holdings plc (NASDAQ:IMCR) to Hold from Buy previously with a price target of $33, down from $48, after assuming coverage. Jefferies has said that Immunocore Holdings plc’s (NASDAQ:IMCR) lead product Kimmtrak addresses a “moderate” total addressable market in uveal melanoma and is nearing peak sales, adding that further upside now depends on pipeline success, where “shots on goal look risky.”

Last month, Immunocore Holdings plc (NASDAQ:IMCR) reported fourth-quarter EPS of (60c), below the (20c) consensus estimate. Revenue came in at $104.5M compared with the $107.77M consensus. Chief Executive Officer Bahija Jallal has said that Immunocore Holdings plc (NASDAQ:IMCR) delivered “a productive year of growth and progress” in 2025, supported by $400M in Kimmtrak sales and continued pipeline development. Bahija Jallal has added that 2026 will focus on executing clinical trials, with key data expected in oncology and the start of its first autoimmune study.

15 States with the Best Healthcare in the US

Immunocore Holdings plc (NASDAQ:IMCR) develops and commercializes immunomodulating therapies targeting cancer, infectious diseases, and autoimmune conditions.

While we acknowledge the potential of IMCR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.